nodes	percent_of_prediction	percent_of_DWPC	metapath
Metoclopramide—Consciousness abnormal—Vincristine—sarcoma	0.0632	0.0703	CcSEcCtD
Metoclopramide—Sunitinib—FLT1—sarcoma	0.0262	0.26	CrCbGaD
Metoclopramide—Altered state of consciousness—Vincristine—sarcoma	0.0237	0.0264	CcSEcCtD
Metoclopramide—Sunitinib—PDGFRB—sarcoma	0.0217	0.215	CrCbGaD
Metoclopramide—Sunitinib—PDGFRA—sarcoma	0.0212	0.209	CrCbGaD
Metoclopramide—Sunitinib—KDR—sarcoma	0.0164	0.163	CrCbGaD
Metoclopramide—Extrapyramidal disorder—Thiotepa—sarcoma	0.0164	0.0183	CcSEcCtD
Metoclopramide—Hepatotoxicity—Dactinomycin—sarcoma	0.0159	0.0177	CcSEcCtD
Metoclopramide—Sunitinib—KIT—sarcoma	0.0155	0.154	CrCbGaD
Metoclopramide—Delirium—Thiotepa—sarcoma	0.0144	0.016	CcSEcCtD
Metoclopramide—Amenorrhoea—Thiotepa—sarcoma	0.0141	0.0156	CcSEcCtD
Metoclopramide—Amenorrhoea—Mitoxantrone—sarcoma	0.0121	0.0135	CcSEcCtD
Metoclopramide—Laryngospasm—Etoposide—sarcoma	0.0119	0.0132	CcSEcCtD
Metoclopramide—Fluid retention—Thiotepa—sarcoma	0.0117	0.0131	CcSEcCtD
Metoclopramide—Hepatotoxicity—Etoposide—sarcoma	0.0115	0.0128	CcSEcCtD
Metoclopramide—Respiratory failure—Vincristine—sarcoma	0.0112	0.0124	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Mitoxantrone—sarcoma	0.00854	0.0095	CcSEcCtD
Metoclopramide—Cardiac arrest—Thiotepa—sarcoma	0.00853	0.00949	CcSEcCtD
Metoclopramide—Rash maculo-papular—Etoposide—sarcoma	0.00807	0.00898	CcSEcCtD
Metoclopramide—Cardiac arrest—Vincristine—sarcoma	0.00756	0.00841	CcSEcCtD
Metoclopramide—Neutropenia—Dactinomycin—sarcoma	0.0072	0.008	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Etoposide—sarcoma	0.00711	0.0079	CcSEcCtD
Metoclopramide—Jaundice—Thiotepa—sarcoma	0.00674	0.0075	CcSEcCtD
Metoclopramide—Agranulocytosis—Thiotepa—sarcoma	0.00645	0.00718	CcSEcCtD
Metoclopramide—Neutropenia—Vincristine—sarcoma	0.00643	0.00715	CcSEcCtD
Metoclopramide—Agranulocytosis—Dactinomycin—sarcoma	0.0064	0.00712	CcSEcCtD
Metoclopramide—Erectile dysfunction—Vincristine—sarcoma	0.00633	0.00704	CcSEcCtD
Metoclopramide—Neutropenia—Mitoxantrone—sarcoma	0.00626	0.00696	CcSEcCtD
Metoclopramide—Hallucination—Thiotepa—sarcoma	0.00617	0.00687	CcSEcCtD
Metoclopramide—Erectile dysfunction—Mitoxantrone—sarcoma	0.00617	0.00686	CcSEcCtD
Metoclopramide—Cardiac arrest—Etoposide—sarcoma	0.00613	0.00682	CcSEcCtD
Metoclopramide—Depression—Vincristine—sarcoma	0.00611	0.0068	CcSEcCtD
Metoclopramide—Drowsiness—Mitoxantrone—sarcoma	0.00597	0.00664	CcSEcCtD
Metoclopramide—Blood disorder—Epirubicin—sarcoma	0.00596	0.00663	CcSEcCtD
Metoclopramide—Jaundice—Mitoxantrone—sarcoma	0.00582	0.00647	CcSEcCtD
Metoclopramide—Delirium—Epirubicin—sarcoma	0.00579	0.00644	CcSEcCtD
Metoclopramide—Flushing—Dactinomycin—sarcoma	0.00572	0.00636	CcSEcCtD
Metoclopramide—Amenorrhoea—Epirubicin—sarcoma	0.00566	0.0063	CcSEcCtD
Metoclopramide—Agranulocytosis—Mitoxantrone—sarcoma	0.00557	0.0062	CcSEcCtD
Metoclopramide—Blood disorder—Doxorubicin—sarcoma	0.00551	0.00613	CcSEcCtD
Metoclopramide—Bronchospasm—Etoposide—sarcoma	0.00548	0.00609	CcSEcCtD
Metoclopramide—Hallucination—Vincristine—sarcoma	0.00548	0.00609	CcSEcCtD
Metoclopramide—Bradycardia—Mitoxantrone—sarcoma	0.00546	0.00607	CcSEcCtD
Metoclopramide—Delirium—Doxorubicin—sarcoma	0.00535	0.00595	CcSEcCtD
Metoclopramide—Dyskinesia—Epirubicin—sarcoma	0.00529	0.00589	CcSEcCtD
Metoclopramide—Nervousness—Thiotepa—sarcoma	0.00525	0.00584	CcSEcCtD
Metoclopramide—Amenorrhoea—Doxorubicin—sarcoma	0.00524	0.00583	CcSEcCtD
Metoclopramide—Neutropenia—Etoposide—sarcoma	0.00521	0.00579	CcSEcCtD
Metoclopramide—Atrioventricular block—Epirubicin—sarcoma	0.00513	0.00571	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Epirubicin—sarcoma	0.00498	0.00554	CcSEcCtD
Metoclopramide—Agitation—Thiotepa—sarcoma	0.00496	0.00552	CcSEcCtD
Metoclopramide—Dyskinesia—Doxorubicin—sarcoma	0.0049	0.00545	CcSEcCtD
Metoclopramide—Jaundice—Etoposide—sarcoma	0.00484	0.00538	CcSEcCtD
Metoclopramide—Leukopenia—Thiotepa—sarcoma	0.00484	0.00538	CcSEcCtD
Metoclopramide—Leukopenia—Dactinomycin—sarcoma	0.0048	0.00534	CcSEcCtD
Metoclopramide—Atrioventricular block—Doxorubicin—sarcoma	0.00475	0.00528	CcSEcCtD
Metoclopramide—Fluid retention—Epirubicin—sarcoma	0.00472	0.00526	CcSEcCtD
Metoclopramide—Convulsion—Thiotepa—sarcoma	0.00468	0.00521	CcSEcCtD
Metoclopramide—Hypertension—Thiotepa—sarcoma	0.00466	0.00519	CcSEcCtD
Metoclopramide—Agranulocytosis—Etoposide—sarcoma	0.00463	0.00515	CcSEcCtD
Metoclopramide—Ventricular tachycardia—Doxorubicin—sarcoma	0.0046	0.00512	CcSEcCtD
Metoclopramide—Anxiety—Thiotepa—sarcoma	0.00458	0.0051	CcSEcCtD
Metoclopramide—Rash maculo-papular—Epirubicin—sarcoma	0.00452	0.00503	CcSEcCtD
Metoclopramide—Confusional state—Thiotepa—sarcoma	0.00445	0.00495	CcSEcCtD
Metoclopramide—Agitation—Vincristine—sarcoma	0.0044	0.0049	CcSEcCtD
Metoclopramide—Oedema—Dactinomycin—sarcoma	0.00438	0.00487	CcSEcCtD
Metoclopramide—Fluid retention—Doxorubicin—sarcoma	0.00437	0.00486	CcSEcCtD
Metoclopramide—Tachycardia—Thiotepa—sarcoma	0.0043	0.00479	CcSEcCtD
Metoclopramide—Leukopenia—Vincristine—sarcoma	0.00429	0.00477	CcSEcCtD
Metoclopramide—Rash maculo-papular—Doxorubicin—sarcoma	0.00418	0.00466	CcSEcCtD
Metoclopramide—Leukopenia—Mitoxantrone—sarcoma	0.00418	0.00465	CcSEcCtD
Metoclopramide—Convulsion—Vincristine—sarcoma	0.00415	0.00462	CcSEcCtD
Metoclopramide—Flushing—Etoposide—sarcoma	0.00414	0.0046	CcSEcCtD
Metoclopramide—Hypertension—Vincristine—sarcoma	0.00414	0.0046	CcSEcCtD
Metoclopramide—Convulsion—Mitoxantrone—sarcoma	0.00404	0.0045	CcSEcCtD
Metoclopramide—Hypertension—Mitoxantrone—sarcoma	0.00403	0.00448	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Epirubicin—sarcoma	0.00398	0.00443	CcSEcCtD
Metoclopramide—Anxiety—Mitoxantrone—sarcoma	0.00396	0.0044	CcSEcCtD
Metoclopramide—Somnolence—Thiotepa—sarcoma	0.00392	0.00436	CcSEcCtD
Metoclopramide—Oedema—Vincristine—sarcoma	0.00391	0.00435	CcSEcCtD
Metoclopramide—Confusional state—Mitoxantrone—sarcoma	0.00384	0.00427	CcSEcCtD
Metoclopramide—Oedema—Mitoxantrone—sarcoma	0.00381	0.00424	CcSEcCtD
Metoclopramide—Fatigue—Thiotepa—sarcoma	0.0038	0.00423	CcSEcCtD
Metoclopramide—Renal impairment—Epirubicin—sarcoma	0.0038	0.00422	CcSEcCtD
Metoclopramide—Fatigue—Dactinomycin—sarcoma	0.00377	0.0042	CcSEcCtD
Metoclopramide—Muscle spasms—Etoposide—sarcoma	0.00373	0.00415	CcSEcCtD
Metoclopramide—Tachycardia—Mitoxantrone—sarcoma	0.00372	0.00413	CcSEcCtD
Metoclopramide—Cardiac failure congestive—Doxorubicin—sarcoma	0.00369	0.0041	CcSEcCtD
Metoclopramide—Hypotension—Vincristine—sarcoma	0.00365	0.00406	CcSEcCtD
Metoclopramide—Feeling abnormal—Thiotepa—sarcoma	0.00363	0.00404	CcSEcCtD
Metoclopramide—Feeling abnormal—Dactinomycin—sarcoma	0.00361	0.00401	CcSEcCtD
Metoclopramide—Hypotension—Mitoxantrone—sarcoma	0.00356	0.00396	CcSEcCtD
Metoclopramide—Insomnia—Vincristine—sarcoma	0.00354	0.00393	CcSEcCtD
Metoclopramide—Renal impairment—Doxorubicin—sarcoma	0.00351	0.00391	CcSEcCtD
Metoclopramide—Urticaria—Thiotepa—sarcoma	0.0035	0.0039	CcSEcCtD
Metoclopramide—Body temperature increased—Thiotepa—sarcoma	0.00349	0.00388	CcSEcCtD
Metoclopramide—Leukopenia—Etoposide—sarcoma	0.00347	0.00386	CcSEcCtD
Metoclopramide—Body temperature increased—Dactinomycin—sarcoma	0.00346	0.00385	CcSEcCtD
Metoclopramide—Cardiac arrest—Epirubicin—sarcoma	0.00343	0.00382	CcSEcCtD
Metoclopramide—Dyspnoea—Mitoxantrone—sarcoma	0.00339	0.00378	CcSEcCtD
Metoclopramide—Somnolence—Mitoxantrone—sarcoma	0.00338	0.00377	CcSEcCtD
Metoclopramide—Fatigue—Vincristine—sarcoma	0.00337	0.00375	CcSEcCtD
Metoclopramide—Convulsion—Etoposide—sarcoma	0.00336	0.00374	CcSEcCtD
Metoclopramide—Hypertension—Etoposide—sarcoma	0.00335	0.00373	CcSEcCtD
Metoclopramide—Fatigue—Mitoxantrone—sarcoma	0.00328	0.00365	CcSEcCtD
Metoclopramide—Hypersensitivity—Thiotepa—sarcoma	0.00325	0.00361	CcSEcCtD
Metoclopramide—Hypersensitivity—Dactinomycin—sarcoma	0.00322	0.00359	CcSEcCtD
Metoclopramide—Confusional state—Etoposide—sarcoma	0.00319	0.00355	CcSEcCtD
Metoclopramide—Cardiac arrest—Doxorubicin—sarcoma	0.00318	0.00354	CcSEcCtD
Metoclopramide—Asthenia—Thiotepa—sarcoma	0.00316	0.00352	CcSEcCtD
Metoclopramide—Asthenia—Dactinomycin—sarcoma	0.00314	0.00349	CcSEcCtD
Metoclopramide—Feeling abnormal—Mitoxantrone—sarcoma	0.00314	0.00349	CcSEcCtD
Metoclopramide—Asthma—Epirubicin—sarcoma	0.00312	0.00347	CcSEcCtD
Metoclopramide—Tachycardia—Etoposide—sarcoma	0.00309	0.00344	CcSEcCtD
Metoclopramide—Body temperature increased—Vincristine—sarcoma	0.00309	0.00344	CcSEcCtD
Metoclopramide—Urticaria—Mitoxantrone—sarcoma	0.00302	0.00336	CcSEcCtD
Metoclopramide—Diarrhoea—Thiotepa—sarcoma	0.00302	0.00336	CcSEcCtD
Metoclopramide—Body temperature increased—Mitoxantrone—sarcoma	0.00301	0.00335	CcSEcCtD
Metoclopramide—Diarrhoea—Dactinomycin—sarcoma	0.00299	0.00333	CcSEcCtD
Metoclopramide—Hypotension—Etoposide—sarcoma	0.00296	0.00329	CcSEcCtD
Metoclopramide—Neutropenia—Epirubicin—sarcoma	0.00292	0.00325	CcSEcCtD
Metoclopramide—Dizziness—Thiotepa—sarcoma	0.00292	0.00324	CcSEcCtD
Metoclopramide—Asthma—Doxorubicin—sarcoma	0.00289	0.00321	CcSEcCtD
Metoclopramide—Pollakiuria—Epirubicin—sarcoma	0.00288	0.00321	CcSEcCtD
Metoclopramide—Hypersensitivity—Vincristine—sarcoma	0.00288	0.0032	CcSEcCtD
Metoclopramide—Dyspnoea—Etoposide—sarcoma	0.00282	0.00314	CcSEcCtD
Metoclopramide—Somnolence—Etoposide—sarcoma	0.00282	0.00313	CcSEcCtD
Metoclopramide—Hypersensitivity—Mitoxantrone—sarcoma	0.00281	0.00312	CcSEcCtD
Metoclopramide—Asthenia—Vincristine—sarcoma	0.00281	0.00312	CcSEcCtD
Metoclopramide—Drowsiness—Epirubicin—sarcoma	0.00278	0.0031	CcSEcCtD
Metoclopramide—Rash—Thiotepa—sarcoma	0.00278	0.00309	CcSEcCtD
Metoclopramide—Dermatitis—Thiotepa—sarcoma	0.00278	0.00309	CcSEcCtD
Metoclopramide—Headache—Thiotepa—sarcoma	0.00276	0.00307	CcSEcCtD
Metoclopramide—Rash—Dactinomycin—sarcoma	0.00276	0.00307	CcSEcCtD
Metoclopramide—Asthenia—Mitoxantrone—sarcoma	0.00273	0.00304	CcSEcCtD
Metoclopramide—Fatigue—Etoposide—sarcoma	0.00273	0.00304	CcSEcCtD
Metoclopramide—Jaundice—Epirubicin—sarcoma	0.00271	0.00302	CcSEcCtD
Metoclopramide—Neutropenia—Doxorubicin—sarcoma	0.0027	0.003	CcSEcCtD
Metoclopramide—Diarrhoea—Vincristine—sarcoma	0.00267	0.00298	CcSEcCtD
Metoclopramide—Pollakiuria—Doxorubicin—sarcoma	0.00267	0.00297	CcSEcCtD
Metoclopramide—Nausea—Thiotepa—sarcoma	0.00262	0.00291	CcSEcCtD
Metoclopramide—Feeling abnormal—Etoposide—sarcoma	0.00261	0.0029	CcSEcCtD
Metoclopramide—Diarrhoea—Mitoxantrone—sarcoma	0.00261	0.0029	CcSEcCtD
Metoclopramide—Nausea—Dactinomycin—sarcoma	0.0026	0.00289	CcSEcCtD
Metoclopramide—Agranulocytosis—Epirubicin—sarcoma	0.0026	0.00289	CcSEcCtD
Metoclopramide—Dizziness—Vincristine—sarcoma	0.00259	0.00288	CcSEcCtD
Metoclopramide—Drowsiness—Doxorubicin—sarcoma	0.00258	0.00287	CcSEcCtD
Metoclopramide—Bradycardia—Epirubicin—sarcoma	0.00254	0.00283	CcSEcCtD
Metoclopramide—Urticaria—Etoposide—sarcoma	0.00252	0.0028	CcSEcCtD
Metoclopramide—Jaundice—Doxorubicin—sarcoma	0.00251	0.00279	CcSEcCtD
Metoclopramide—Body temperature increased—Etoposide—sarcoma	0.0025	0.00279	CcSEcCtD
Metoclopramide—Rash—Vincristine—sarcoma	0.00247	0.00274	CcSEcCtD
Metoclopramide—Dermatitis—Vincristine—sarcoma	0.00246	0.00274	CcSEcCtD
Metoclopramide—Headache—Vincristine—sarcoma	0.00245	0.00272	CcSEcCtD
Metoclopramide—Visual impairment—Epirubicin—sarcoma	0.00241	0.00268	CcSEcCtD
Metoclopramide—Agranulocytosis—Doxorubicin—sarcoma	0.0024	0.00267	CcSEcCtD
Metoclopramide—Rash—Mitoxantrone—sarcoma	0.0024	0.00267	CcSEcCtD
Metoclopramide—Dermatitis—Mitoxantrone—sarcoma	0.0024	0.00267	CcSEcCtD
Metoclopramide—Headache—Mitoxantrone—sarcoma	0.00239	0.00265	CcSEcCtD
Metoclopramide—Bradycardia—Doxorubicin—sarcoma	0.00235	0.00262	CcSEcCtD
Metoclopramide—Hypersensitivity—Etoposide—sarcoma	0.00233	0.0026	CcSEcCtD
Metoclopramide—Nausea—Vincristine—sarcoma	0.00232	0.00258	CcSEcCtD
Metoclopramide—Flushing—Epirubicin—sarcoma	0.00232	0.00258	CcSEcCtD
Metoclopramide—Asthenia—Etoposide—sarcoma	0.00227	0.00253	CcSEcCtD
Metoclopramide—Nausea—Mitoxantrone—sarcoma	0.00226	0.00252	CcSEcCtD
Metoclopramide—Visual impairment—Doxorubicin—sarcoma	0.00223	0.00248	CcSEcCtD
Metoclopramide—Diarrhoea—Etoposide—sarcoma	0.00217	0.00241	CcSEcCtD
Metoclopramide—Flushing—Doxorubicin—sarcoma	0.00215	0.00239	CcSEcCtD
Metoclopramide—Nervousness—Epirubicin—sarcoma	0.00211	0.00235	CcSEcCtD
Metoclopramide—Dizziness—Etoposide—sarcoma	0.00209	0.00233	CcSEcCtD
Metoclopramide—Muscle spasms—Epirubicin—sarcoma	0.00209	0.00233	CcSEcCtD
Metoclopramide—Agitation—Epirubicin—sarcoma	0.002	0.00222	CcSEcCtD
Metoclopramide—Rash—Etoposide—sarcoma	0.002	0.00222	CcSEcCtD
Metoclopramide—Dermatitis—Etoposide—sarcoma	0.002	0.00222	CcSEcCtD
Metoclopramide—Headache—Etoposide—sarcoma	0.00198	0.00221	CcSEcCtD
Metoclopramide—Nervousness—Doxorubicin—sarcoma	0.00195	0.00217	CcSEcCtD
Metoclopramide—Leukopenia—Epirubicin—sarcoma	0.00195	0.00217	CcSEcCtD
Metoclopramide—Muscle spasms—Doxorubicin—sarcoma	0.00194	0.00215	CcSEcCtD
Metoclopramide—Palpitations—Epirubicin—sarcoma	0.00192	0.00214	CcSEcCtD
Metoclopramide—Convulsion—Epirubicin—sarcoma	0.00188	0.0021	CcSEcCtD
Metoclopramide—Nausea—Etoposide—sarcoma	0.00188	0.00209	CcSEcCtD
Metoclopramide—Hypertension—Epirubicin—sarcoma	0.00188	0.00209	CcSEcCtD
Metoclopramide—Agitation—Doxorubicin—sarcoma	0.00185	0.00206	CcSEcCtD
Metoclopramide—Anxiety—Epirubicin—sarcoma	0.00185	0.00205	CcSEcCtD
Metoclopramide—Leukopenia—Doxorubicin—sarcoma	0.0018	0.002	CcSEcCtD
Metoclopramide—Confusional state—Epirubicin—sarcoma	0.00179	0.00199	CcSEcCtD
Metoclopramide—Palpitations—Doxorubicin—sarcoma	0.00178	0.00198	CcSEcCtD
Metoclopramide—Oedema—Epirubicin—sarcoma	0.00178	0.00197	CcSEcCtD
Metoclopramide—Convulsion—Doxorubicin—sarcoma	0.00174	0.00194	CcSEcCtD
Metoclopramide—Hypertension—Doxorubicin—sarcoma	0.00174	0.00193	CcSEcCtD
Metoclopramide—Tachycardia—Epirubicin—sarcoma	0.00173	0.00193	CcSEcCtD
Metoclopramide—Anxiety—Doxorubicin—sarcoma	0.00171	0.0019	CcSEcCtD
Metoclopramide—Hypotension—Epirubicin—sarcoma	0.00166	0.00185	CcSEcCtD
Metoclopramide—Confusional state—Doxorubicin—sarcoma	0.00166	0.00184	CcSEcCtD
Metoclopramide—Oedema—Doxorubicin—sarcoma	0.00164	0.00183	CcSEcCtD
Metoclopramide—Insomnia—Epirubicin—sarcoma	0.00161	0.00179	CcSEcCtD
Metoclopramide—Tachycardia—Doxorubicin—sarcoma	0.0016	0.00178	CcSEcCtD
Metoclopramide—Dyspnoea—Epirubicin—sarcoma	0.00158	0.00176	CcSEcCtD
Metoclopramide—Somnolence—Epirubicin—sarcoma	0.00158	0.00176	CcSEcCtD
Metoclopramide—Hypotension—Doxorubicin—sarcoma	0.00153	0.00171	CcSEcCtD
Metoclopramide—Fatigue—Epirubicin—sarcoma	0.00153	0.0017	CcSEcCtD
Metoclopramide—Insomnia—Doxorubicin—sarcoma	0.00149	0.00165	CcSEcCtD
Metoclopramide—Dyspnoea—Doxorubicin—sarcoma	0.00146	0.00163	CcSEcCtD
Metoclopramide—Feeling abnormal—Epirubicin—sarcoma	0.00146	0.00163	CcSEcCtD
Metoclopramide—Somnolence—Doxorubicin—sarcoma	0.00146	0.00162	CcSEcCtD
Metoclopramide—Fatigue—Doxorubicin—sarcoma	0.00142	0.00158	CcSEcCtD
Metoclopramide—Urticaria—Epirubicin—sarcoma	0.00141	0.00157	CcSEcCtD
Metoclopramide—Body temperature increased—Epirubicin—sarcoma	0.0014	0.00156	CcSEcCtD
Metoclopramide—Feeling abnormal—Doxorubicin—sarcoma	0.00135	0.00151	CcSEcCtD
Metoclopramide—Hypersensitivity—Epirubicin—sarcoma	0.00131	0.00146	CcSEcCtD
Metoclopramide—Urticaria—Doxorubicin—sarcoma	0.0013	0.00145	CcSEcCtD
Metoclopramide—Body temperature increased—Doxorubicin—sarcoma	0.0013	0.00144	CcSEcCtD
Metoclopramide—Asthenia—Epirubicin—sarcoma	0.00127	0.00142	CcSEcCtD
Metoclopramide—Diarrhoea—Epirubicin—sarcoma	0.00121	0.00135	CcSEcCtD
Metoclopramide—Hypersensitivity—Doxorubicin—sarcoma	0.00121	0.00135	CcSEcCtD
Metoclopramide—Asthenia—Doxorubicin—sarcoma	0.00118	0.00131	CcSEcCtD
Metoclopramide—Dizziness—Epirubicin—sarcoma	0.00117	0.00131	CcSEcCtD
Metoclopramide—Diarrhoea—Doxorubicin—sarcoma	0.00112	0.00125	CcSEcCtD
Metoclopramide—Rash—Epirubicin—sarcoma	0.00112	0.00125	CcSEcCtD
Metoclopramide—Dermatitis—Epirubicin—sarcoma	0.00112	0.00124	CcSEcCtD
Metoclopramide—Headache—Epirubicin—sarcoma	0.00111	0.00124	CcSEcCtD
Metoclopramide—Dizziness—Doxorubicin—sarcoma	0.00109	0.00121	CcSEcCtD
Metoclopramide—Nausea—Epirubicin—sarcoma	0.00105	0.00117	CcSEcCtD
Metoclopramide—Rash—Doxorubicin—sarcoma	0.00104	0.00115	CcSEcCtD
Metoclopramide—Dermatitis—Doxorubicin—sarcoma	0.00103	0.00115	CcSEcCtD
Metoclopramide—Headache—Doxorubicin—sarcoma	0.00103	0.00114	CcSEcCtD
Metoclopramide—Nausea—Doxorubicin—sarcoma	0.000976	0.00109	CcSEcCtD
